Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?

Abstract

Therapeutic options in immune-mediated thrombotic thrombocytopenic purpura (iTTP) during pregnancy are limited besides therapeutic plasma exchange (TPE) and corticosteroids. The report by Odetola et al. suggests that caplacizumab represents a reasonable option in iTTP during pregnancy, especially when the disease is not rapidly controlled with the standard TPE-corticosteroid association. Commentary on: Odetola et al. Safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpura. Br J Haematol 2023;202:879-882.

• Authors: Paul Coppo, Bérangère S Joly, French Reference Center for Thrombotic Microangiopathies (CNR-MAT)
• Journal: British journal of haematology (Br J Haematol) Vol. 202 Issue 4 Pg. 725-727 (08 2023) ISSN: 1365-2141 [Electronic] England
• PMID: 37291806 (Publication Type: Journal Article)
• Copyright: © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• caplacizumab
• von Willebrand Factor
• Single-Domain Antibodies
• Adrenal Cortex Hormones
• ADAMTS13 Protein

Topics

• Humans
• Pregnancy
• Female
• Purpura, Thrombotic Thrombocytopenic (drug therapy)
• von Willebrand Factor
• Single-Domain Antibodies (therapeutic use)
• Adrenal Cortex Hormones (therapeutic use)
• Plasma Exchange
• ADAMTS13 Protein